Garcia Marino 4
4 · Dianthus Therapeutics, Inc. /DE/ · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Dianthus (DNTH) CEO Garcia Marino Exercises Options, Sells Shares
What Happened
Garcia Marino, CEO, President and Director of Dianthus Therapeutics (DNTH), exercised 122,918 option-derived shares on March 12, 2026 at $6.70 per share (cost $823,551) and sold those same 122,918 shares in multiple open-market transactions that day for aggregate proceeds of approximately $10.02 million. The sales were executed under a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date: March 12, 2026; Form 4 filed March 13, 2026 (timely filing).
- Exercise: 122,918 shares acquired at $6.70 each — total cash paid $823,551.
- Sales (total disposed = 122,918 shares; total proceeds ≈ $10,016,381):
- 43,505 shares @ weighted avg $80.69 (prices in range $80.29–$81.28) — $3,510,418.
- 65,517 shares @ weighted avg $81.74 (range $81.29–$82.25) — $5,355,360.
- 12,796 shares @ weighted avg $82.60 (range $82.29–$83.23) — $1,056,950.
- 200 shares @ $83.38 — $16,676.
- 900 shares @ $85.53 — $76,977.
- An additional derivative-line shows 122,918 shares reported as disposed at $0.00 (reporting of the exercised conversion).
- Footnotes: trades executed pursuant to a Rule 10b5-1 plan adopted Nov 17, 2025; several weighted-average price notes provide the price ranges for the multiple transactions; original option vesting schedule noted.
- Shares owned after the transactions: not disclosed in the excerpt of this filing.
Context
Because the shares were acquired by exercising options and then sold the same day, this is effectively a cashless exercise (exercise + immediate sale). Sales executed under a 10b5-1 plan are pre-arranged and are often routine executions of planned dispositions rather than ad hoc signals of insider sentiment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-03-12$6.70/sh+122,918$823,551→ 122,918 total - Sale
Common Stock
[F1][F2]2026-03-12$80.69/sh−43,505$3,510,418→ 79,413 total - Sale
Common Stock
[F1][F3]2026-03-12$81.74/sh−65,517$5,355,360→ 13,896 total - Sale
Common Stock
[F1][F4]2026-03-12$82.60/sh−12,796$1,056,950→ 1,100 total - Sale
Common Stock
[F1]2026-03-12$83.38/sh−200$16,676→ 900 total - Sale
Common Stock
[F1]2026-03-12$85.53/sh−900$76,977→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-03-12−122,918→ 59,741 totalExercise: $6.70Exp: 2031-11-03→ Common Stock (122,918 underlying)
Footnotes (5)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.29 to $81.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.29 to $82.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.29 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.